As of the latest Form 4 filed Jul 2, 2026.
What Emergent Biosolutions Inc insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Buys plotted up, sells down; bar height is the disclosed dollar value (shares × reported price). Our Form 4 history is only complete from mid-2026, so early months are sparse — the series fills in as more filings land. Open-market purchases and sales only.
Newest filing first — the 37 most recent filings for EBS.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-07-02 | 2026-07-01 | Williams Paul Anthony SVP, Products Business | SSale | −3.00K | $8.40 | $25.2K | Yes (planned) | Form 4 ↗ |
| 2026-06-10 | 2026-06-08 | Hartzel William SVP, Bioservices | FTax | −1.74K | $8.00 | $13.9K | No | Form 4 ↗ |
| 2026-06-10 | 2026-06-08 | Williams Paul Anthony SVP, Products Business | FTax | −694.00 | $8.00 | $5.55K | No | Form 4 ↗ |
| 2026-06-10 | 2026-06-08 | Glessner Coleen EVP, Quality & Ethics, and CPL | FTax | −2.02K | $8.00 | $16.1K | No | Form 4 ↗ |
| 2026-06-10 | 2026-06-08 | LINDAHL RICHARD S EVP, Chief Financial Officer | FTax | −3.96K | $8.00 | $31.7K | No | Form 4 ↗ |
| 2026-05-04 | 2026-05-01 | Zoon Kathryn C Director | SSale | −1.06K | $8.97 | $9.48K | Yes (planned) | Form 4 ↗ |
| 2026-05-04 | 2026-05-01 | Zoon Kathryn C, Director | SSale | −16.1K | $8.36 | $135K | Yes (planned) | Form 4 ↗ |
| 2026-05-04 | 2026-05-01 | DeGolyer Donald W Director | SSale | −954.00 | $8.96 | $8.55K | Yes (planned) | Form 4 ↗ |
| 2026-05-04 | 2026-05-01 | DeGolyer Donald W, Director | SSale | −14.5K | $8.36 | $121K | Yes (planned) | Form 4 ↗ |
| 2026-05-04 | 2026-05-01 | Dayal Sujata Tyagi Director | SSale | −980.00 | $8.94 | $8.76K | Yes (planned) | Form 4 ↗ |
| 2026-05-04 | 2026-05-01 | Dayal Sujata Tyagi, Director | SSale | −12.8K | $8.36 | $107K | Yes (planned) | Form 4 ↗ |
| 2026-05-04 | 2026-04-30 | Zoon Kathryn C Director | AAward | +25.3K | $0.00 | $0.00 | Yes (planned) | Form 4 ↗ |
| 2026-05-04 | 2026-04-30 | DeGolyer Donald W Director | AAward | +25.3K | $0.00 | $0.00 | Yes (planned) | Form 4 ↗ |
| 2026-05-04 | 2026-04-30 | Dayal Sujata Tyagi Director | AAward | +25.3K | $0.00 | $0.00 | Yes (planned) | Form 4 ↗ |
| 2026-05-04 | 2026-04-30 | Fowler Neal Franklin Director | AAward | +25.3K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-04 | 2026-04-30 | White Marvin L Director | AAward | +25.3K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-04 | 2026-04-30 | Harsanyi Zsolt Chairman | AAward | +25.3K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-04 | 2026-04-30 | Richard Ronald Director | AAward | +25.3K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-04 | 2026-04-30 | Katkin Keith Director | SSale | −15.5K | $8.28 | $128K | Yes (planned) | Form 4 ↗ |
| 2026-05-04 | 2026-04-30 | Katkin Keith, Director | AAward | +25.3K | $0.00 | $0.00 | Yes (planned) | Form 4 ↗ |
| 2026-05-04 | 2026-04-30 | FOWLER JOHN D JR Director | AAward | +25.3K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-01 | 2026-04-29 | Lowry Simon C SVP, R&D, CMO | AAward | +100K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-01 | 2026-04-29 | Perl Jessica SVP, General Counsel, Corp Sec | AAward | +104K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-01 | 2026-04-29 | Hartzel William SVP, Bioservices | AAward | +100K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-01 | 2026-04-29 | Williams Paul Anthony SVP, Products Business | AAward | +100K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-01 | 2026-04-29 | Glessner Coleen EVP, Quality & Ethics, and CPL | AAward | +100K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-01 | 2026-04-29 | PAPA JOSEPH C President and CEO | AAward | +188K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-01 | 2026-04-29 | LINDAHL RICHARD S EVP, Chief Financial Officer | AAward | +163K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-04-03 | 2026-04-01 | Williams Paul Anthony SVP, Products Business | SSale | −4.00K | $8.44 | $33.8K | Yes (planned) | Form 4 ↗ |
| 2026-03-05 | 2026-03-05 | Lowry Simon C SVP, R&D, CMO | FTax | −10.6K | $8.44 | $89.8K | No | Form 4 ↗ |
| 2026-03-05 | 2026-03-05 | Perl Jessica SVP, General Counsel, Corp Sec | FTax | −6.46K | $8.44 | $54.6K | No | Form 4 ↗ |
| 2026-03-05 | 2026-03-05 | Hartzel William SVP, Bioservices | FTax | −9.49K | $8.44 | $80.1K | No | Form 4 ↗ |
| 2026-03-05 | 2026-03-05 | Williams Paul Anthony SVP, Products Business | FTax | −9.40K | $8.44 | $79.3K | No | Form 4 ↗ |
| 2026-03-05 | 2026-03-05 | Glessner Coleen EVP, Quality & Ethics, and CPL | FTax | −8.20K | $8.44 | $69.2K | No | Form 4 ↗ |
| 2026-03-05 | 2026-03-05 | PAPA JOSEPH C President and CEO | FTax | −37.1K | $8.44 | $313K | No | Form 4 ↗ |
| 2026-03-05 | 2026-03-05 | LINDAHL RICHARD S EVP, Chief Financial Officer | FTax | −23.6K | $8.44 | $200K | No | Form 4 ↗ |
| 2026-03-05 | 2026-03-03 | FOWLER JOHN D JR Director | AAward | +5.01K | $8.99 | $45.0K | No | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also EBS’s full analysis or the market-wide insider trading feed. The tabs above jump to EBS’s other SEC data.
Source: SEC Form 4 filings for EBS, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.